I Judson

Therapiekonzepte bei non-responden/rezidivpatienten mit Eing Sarkomen im kindesalter.

Jeremy Whelan, B. Fröhlich, Michael Paulussen, 1999 .

Advances in the treatment of gastrointestinal stromal tumours.

I Judson, G. Demetri, I. Judson, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

I Judson, M. Dowsett, D. Dearnaley, 2004, British Journal of Cancer.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

I Judson, J Verweij, J. Blay, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

I Judson, I. Judson, U. Banerji, 2009, British Journal of Cancer.

A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy

M O Leach, I Judson, M Tracy, 2009, British Journal of Cancer.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P Reichardt, I Judson, Robin L. Jones, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.